Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Correction to: Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think.

Luque JS, Wallace K, Blankenship BF, Roos LG, Berger FG, LaPelle NR, Melvin CL.

J Community Health. 2018 Jun 7. doi: 10.1007/s10900-018-0534-9. [Epub ahead of print]

PMID:
29882181
2.

Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think.

Luque JS, Wallace K, Blankenship BF, Roos LG, Berger FG, LaPelle NR, Melvin CL.

J Community Health. 2018 May 16. doi: 10.1007/s10900-018-0525-x. [Epub ahead of print] Erratum in: J Community Health. 2018 Jun 7;:.

PMID:
29767821
3.

Antibiotic-mediated bacteriome depletion in ApcMin/+ mice is associated with reduction in mucus-producing goblet cells and increased colorectal cancer progression.

Kaur K, Saxena A, Debnath I, O'Brien JL, Ajami NJ, Auchtung TA, Petrosino JF, Sougiannis AJ, Depaep S, Chumanevich A, Gummadidala PM, Omebeyinje MH, Banerjee S, Chatzistamou I, Chakraborty P, Fayad R, Berger FG, Carson JA, Chanda A.

Cancer Med. 2018 May;7(5):2003-2012. doi: 10.1002/cam4.1460. Epub 2018 Apr 6.

4.

Functional characterization of the mouse Serpina1 paralog DOM-7.

Jülicher K, Wähner A, Haase K, Barbour KW, Berger FG, Wiehlmann L, Davenport C, Schuster-Gossler K, Stitz J, Cantz T, Eggenschwiler R.

Biol Chem. 2018 May 24;399(6):577-582. doi: 10.1515/hsz-2018-0154.

PMID:
29498931
5.

A statewide program providing colorectal cancer screening to the uninsured of South Carolina.

Eberth JM, Thibault A, Caldwell R, Josey MJ, Qiang B, Peña E, LaFrance D, Berger FG.

Cancer. 2018 May 1;124(9):1912-1920. doi: 10.1002/cncr.31250. Epub 2018 Feb 7.

PMID:
29415338
6.

Cyclic-GMP-Elevating Agents Suppress Polyposis in ApcMin mice by Targeting the Preneoplastic Epithelium.

Sharman SK, Islam BN, Hou Y, Singh N, Berger FG, Sridhar S, Yoo W, Browning DD.

Cancer Prev Res (Phila). 2018 Feb;11(2):81-92. doi: 10.1158/1940-6207.CAPR-17-0267. Epub 2018 Jan 4.

PMID:
29301746
7.

Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.

PMID:
29200350
8.

HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.

Chandrashekaran V, Seth RK, Dattaroy D, Alhasson F, Ziolenka J, Carson J, Berger FG, Kalyanaraman B, Diehl AM, Chatterjee S.

Redox Biol. 2017 Oct;13:8-19. doi: 10.1016/j.redox.2017.05.005. Epub 2017 May 10.

9.

Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.

Islam BN, Sharman SK, Hou Y, Bridges AE, Singh N, Kim S, Kolhe R, Trillo-Tinoco J, Rodriguez PC, Berger FG, Sridhar S, Browning DD.

Cancer Prev Res (Phila). 2017 Jul;10(7):377-388. doi: 10.1158/1940-6207.CAPR-17-0015. Epub 2017 May 3.

10.

Oxidative Stress and Response to Thymidylate Synthase-Targeted Antimetabolites.

Ozer U, Barbour KW, Clinton SA, Berger FG.

Mol Pharmacol. 2015 Dec;88(6):970-81. doi: 10.1124/mol.115.099614. Epub 2015 Oct 6.

11.

Race and Prevalence of Large Bowel Polyps Among the Low-Income and Uninsured in South Carolina.

Wallace K, Brandt HM, Bearden JD, Blankenship BF, Caldwell R, Dunn J, Hegedus P, Hoffman BJ, Marsh CH, Marsh WH, Melvin CL, Seabrook ME, Sterba RE, Stinson ML, Thibault A, Berger FG, Alberg AJ.

Dig Dis Sci. 2016 Jan;61(1):265-72. doi: 10.1007/s10620-015-3862-y. Epub 2015 Sep 19.

12.

Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina.

van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I.

Health Serv Res. 2015 Jun;50(3):768-89. doi: 10.1111/1475-6773.12246. Epub 2014 Oct 16.

13.

A unique form of haptoglobin produced by murine hematopoietic cells supports B-cell survival, differentiation and immune response.

Huntoon KM, Russell L, Tracy E, Barbour KW, Li Q, Shrikant PA, Berger FG, Garrett-Sinha LA, Baumann H.

Mol Immunol. 2013 Oct;55(3-4):345-54. doi: 10.1016/j.molimm.2013.03.008. Epub 2013 Mar 30.

14.

Racial disparities in advanced-stage colorectal cancer survival.

Wallace K, Hill EG, Lewin DN, Williamson G, Oppenheimer S, Ford ME, Wargovich MJ, Berger FG, Bolick SW, Thomas MB, Alberg AJ.

Cancer Causes Control. 2013 Mar;24(3):463-71. doi: 10.1007/s10552-012-0133-5. Epub 2013 Jan 8.

15.

Characterization of the bipartite degron that regulates ubiquitin-independent degradation of thymidylate synthase.

Barbour KW, Xing YY, Peña EA, Berger FG.

Biosci Rep. 2013 Jan 18;33(1):165-73. doi: 10.1042/BSR20120112.

16.

Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas.

Lo PK, Lee JS, Chen H, Reisman D, Berger FG, Sukumar S.

Exp Mol Pathol. 2013 Feb;94(1):262-9. doi: 10.1016/j.yexmp.2012.10.014. Epub 2012 Oct 24.

17.

Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1.

McClellan JL, Davis JM, Steiner JL, Enos RT, Jung SH, Carson JA, Pena MM, Carnevale KA, Berger FG, Murphy EA.

Am J Physiol Gastrointest Liver Physiol. 2012 Nov 15;303(10):G1087-95. doi: 10.1152/ajpgi.00252.2012. Epub 2012 Sep 27.

18.

Relationship of colorectal cancer awareness and knowledge with colorectal cancer screening.

Brandt HM, Dolinger HR, Sharpe PA, Hardin JW, Berger FG.

Colorectal Cancer. 2012;1(5):383-396.

19.

CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.

Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, Chen H.

Oncogene. 2012 May 24;31(21):2614-26. doi: 10.1038/onc.2011.439. Epub 2011 Sep 26.

20.

Cooperation between an intrinsically disordered region and a helical segment is required for ubiquitin-independent degradation by the proteasome.

Melo SP, Barbour KW, Berger FG.

J Biol Chem. 2011 Oct 21;286(42):36559-67. doi: 10.1074/jbc.M111.274258. Epub 2011 Aug 30.

21.

USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1.

Zhang X, Berger FG, Yang J, Lu X.

EMBO J. 2011 Jun 1;30(11):2177-89. doi: 10.1038/emboj.2011.125. Epub 2011 Apr 26.

22.

Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in Apc Min/+ mice.

Davis C, Price R, Acharya G, Baudino T, Borg T, Berger FG, Peña MM.

Microsc Microanal. 2011 Aug;17(4):528-39. doi: 10.1017/S1431927611000043. Epub 2011 Apr 8.

23.

The ATM kinase induces microRNA biogenesis in the DNA damage response.

Zhang X, Wan G, Berger FG, He X, Lu X.

Mol Cell. 2011 Feb 18;41(4):371-83. doi: 10.1016/j.molcel.2011.01.020.

24.

Functional dissection of the N-terminal degron of human thymidylate synthase.

Melo SP, Yoshida A, Berger FG.

Biochem J. 2010 Nov 15;432(1):217-26. doi: 10.1042/BJ20101027.

PMID:
20815815
25.

Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.

Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X.

Cancer Res. 2010 Sep 15;70(18):7176-86. doi: 10.1158/0008-5472.CAN-10-0697. Epub 2010 Jul 28.

26.

Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.

Baltgalvis KA, Berger FG, Peña MM, Mark Davis J, White JP, Carson JA.

J Appl Physiol (1985). 2010 Oct;109(4):1155-61. doi: 10.1152/japplphysiol.00442.2010. Epub 2010 Jul 22.

27.

Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .

Huang X, Gibson LM, Bell BJ, Lovelace LL, Peña MM, Berger FG, Berger SH, Lebioda L.

Biochemistry. 2010 Mar 23;49(11):2475-82. doi: 10.1021/bi901457e.

28.

The intrinsically disordered N-terminal domain of thymidylate synthase targets the enzyme to the ubiquitin-independent proteasomal degradation pathway.

Peña MM, Melo SP, Xing YY, White K, Barbour KW, Berger FG.

J Biol Chem. 2009 Nov 13;284(46):31597-607. doi: 10.1074/jbc.M109.038455. Epub 2009 Sep 21.

29.

The interaction of a high-fat diet and regular moderate intensity exercise on intestinal polyp development in Apc Min/+ mice.

Baltgalvis KA, Berger FG, Peña MM, Davis JM, Carson JA.

Cancer Prev Res (Phila). 2009 Jul;2(7):641-9. doi: 10.1158/1940-6207.CAPR-09-0017. Epub 2009 Jun 23.

30.

Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein.

Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST.

J Biol Chem. 2009 Jul 3;284(27):18292-301. doi: 10.1074/jbc.M109.017202. Epub 2009 May 11.

31.

Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice.

Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, Xiong Y, Berger FG, Peña MM, Hrushesky WJ.

J Biochem. 2009 Mar;145(3):289-97. doi: 10.1093/jb/mvn167. Epub 2008 Dec 23.

PMID:
19106159
32.

Period 2 mutation accelerates ApcMin/+ tumorigenesis.

Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña MM, Hrushesky WJ.

Mol Cancer Res. 2008 Nov;6(11):1786-93. doi: 10.1158/1541-7786.MCR-08-0196.

33.

Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse.

Baltgalvis KA, Berger FG, Peña MM, Davis JM, White JP, Carson JA.

Pflugers Arch. 2009 Mar;457(5):989-1001. doi: 10.1007/s00424-008-0574-6. Epub 2008 Aug 19.

34.

Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer.

Ghatak S, Hascall VC, Berger FG, Penas MM, Davis C, Jabari E, He X, Norris JS, Dang Y, Markwald RR, Misra S.

Connect Tissue Res. 2008;49(3):265-9. doi: 10.1080/03008200802147845.

PMID:
18661357
35.

Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer.

Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S.

Connect Tissue Res. 2008;49(3):219-24. doi: 10.1080/03008200802143356. Review.

PMID:
18661347
36.

Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer.

Thangaraju M, Cresci G, Itagaki S, Mellinger J, Browning DD, Berger FG, Prasad PD, Ganapathy V.

J Gastrointest Surg. 2008 Oct;12(10):1773-81; discussion 1781-2. doi: 10.1007/s11605-008-0573-0. Epub 2008 Jul 26.

PMID:
18661192
37.

The acute phase protein haptoglobin regulates host immunity.

Huntoon KM, Wang Y, Eppolito CA, Barbour KW, Berger FG, Shrikant PA, Baumann H.

J Leukoc Biol. 2008 Jul;84(1):170-81. doi: 10.1189/jlb.0208100. Epub 2008 Apr 24.

38.

Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells.

Misra S, Obeid LM, Hannun YA, Minamisawa S, Berger FG, Markwald RR, Toole BP, Ghatak S.

J Biol Chem. 2008 May 23;283(21):14335-44. doi: 10.1074/jbc.M703811200. Epub 2008 Mar 7.

39.

Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis.

Kwon IK, Schoenlein PV, Delk J, Liu K, Thangaraju M, Dulin NO, Ganapathy V, Berger FG, Browning DD.

Cancer. 2008 Apr 1;112(7):1462-70. doi: 10.1002/cncr.23334.

40.

Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps.

Baltgalvis KA, Berger FG, Peña MM, Davis JM, Carson JA.

J Appl Physiol (1985). 2008 Apr;104(4):1137-43. doi: 10.1152/japplphysiol.00955.2007. Epub 2008 Jan 31.

41.

Interleukin-6 and cachexia in ApcMin/+ mice.

Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA.

Am J Physiol Regul Integr Comp Physiol. 2008 Feb;294(2):R393-401. Epub 2007 Dec 5.

42.

Cell death in response to antimetabolites directed at thymidylate synthase.

Barbour KW, Berger FG.

Cancer Chemother Pharmacol. 2008 Feb;61(2):189-201. Epub 2007 Mar 30.

PMID:
17396263
43.

Polyamine metabolism and tumorigenesis in the Apc(Min/+) mouse.

Berger FG, Kramer DL, Porter CW.

Biochem Soc Trans. 2007 Apr;35(Pt 2):336-9.

PMID:
17371273
44.

Haptoglobin genotype determines myocardial infarct size in diabetic mice.

Blum S, Asaf R, Guetta J, Miller-Lotan R, Asleh R, Kremer R, Levy NS, Berger FG, Aronson D, Fu X, Zhang R, Hazen SL, Levy AP.

J Am Coll Cardiol. 2007 Jan 2;49(1):82-7. Epub 2006 Dec 13.

45.

Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?

Berger FG, Berger SH.

Cancer Biol Ther. 2006 Sep;5(9):1238-41. Epub 2006 Sep 13. No abstract available.

PMID:
17035726
46.

Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice.

You S, Ohmori M, Peña MM, Nassri B, Quiton J, Al-Assad ZA, Liu L, Wood PA, Berger SH, Liu Z, Wyatt MD, Price RL, Berger FG, Hrushesky WJ.

Int J Exp Pathol. 2006 Jun;87(3):227-36.

47.

Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse.

Mehl KA, Davis JM, Berger FG, Carson JA.

J Appl Physiol (1985). 2005 Dec;99(6):2379-87.

48.

Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase.

Peña MM, Xing YY, Koli S, Berger FG.

Biochem J. 2006 Feb 15;394(Pt 1):355-63.

49.

Potent modulation of intestinal tumorigenesis in Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase.

Tucker JM, Murphy JT, Kisiel N, Diegelman P, Barbour KW, Davis C, Medda M, Alhonen L, Jänne J, Kramer DL, Porter CW, Berger FG.

Cancer Res. 2005 Jun 15;65(12):5390-8.

50.

Decreased intestinal polyp multiplicity is related to exercise mode and gender in ApcMin/+ mice.

Mehl KA, Davis JM, Clements JM, Berger FG, Pena MM, Carson JA.

J Appl Physiol (1985). 2005 Jun;98(6):2219-25.

Supplemental Content

Loading ...
Support Center